The receipt of a Notice of Allowance from the U.S. Patent Office is a critical step in securing intellectual property rights, which can significantly impact a company's competitive edge, especially in the high-stakes medical technology industry. For Nexalin Technology, this development not only enhances its product portfolio but also positions the company as a key player in the treatment of neurodegenerative diseases. Given the high prevalence and unmet medical need in conditions like Alzheimer's and dementia, innovations in this area are likely to be well-received by the market, potentially leading to increased investor interest and a positive impact on the company's stock price in the short term.